Abbott has released promising 12-month results from its Volt CE Mark Study, demonstrating the sustained safety and effectiveness of the Volt™ Pulsed Field Ablation (PFA) System for treating atrial fibrillation (AFib). Presented at the 2025 Heart Rhythm Society (HRS) annual meeting, the data highlights significant advancements in AFib therapy, offering new hope for patients suffering from this chronic heart condition.
Exceptional Performance in Diverse Patient Groups
The Volt PFA System was evaluated in two distinct patient categories: those with paroxysmal atrial fibrillation (PAF) and persistent AFib (PersAF). After a year, 83.5% of PAF patients and 58.1% of PersAF patients remained free from atrial arrhythmia. These figures represent some of the lowest recurrence rates observed in long-term PFA studies to date. Additionally, the system achieved these results with an average of only 4.7 therapy applications per vein, outperforming competing PFA technologies.
Enhanced Patient Quality of Life and Safety
Patients reported significant improvements in quality of life, with assessment scores rising from 64.1 to 88.1 over twelve months. The Volt PFA System also showcased an excellent safety profile, with only 2.7% of patients experiencing primary safety endpoint events. Importantly, there were no cases of hemolysis, coronary artery spasm, pulmonary vein stenosis, acute kidney injury, or phrenic nerve injury, addressing common concerns associated with PFA therapy.
– The Volt PFA System delivers effective treatment with fewer applications, enhancing procedural efficiency.
– High retention rates free from arrhythmia indicate robust long-term effectiveness.
– Superior safety outcomes reduce the risk of severe complications.
– Improved quality of life scores reflect meaningful patient benefits.
– Single-catheter approach offers greater procedural flexibility and ease.
The Volt PFA System’s performance across both PAF and PersAF patient groups underscores its versatility and reliability in clinical settings. Its ability to maintain high efficacy with a minimal number of applications makes it a standout option for electrophysiologists aiming to provide optimal care.
Looking ahead, Abbott aims to expand the use of the Volt PFA System, leveraging its proven benefits to treat a broader patient population. The system’s compatibility with both light sedation and general anesthesia further enhances its adaptability in various clinical environments, facilitating smoother workflows and improved patient experiences.
Innovations like the Volt PFA System are pivotal in advancing AFib treatment, offering safer and more effective options for patients. As the technology gains wider adoption, it is expected to set new standards in cardiac ablation therapy, ultimately improving patient outcomes and quality of life on a global scale.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
